119924-26-4

Basic information

• Product Name: furan-2-acrylic acid azide
• Synonyms: furan-2-acrylic acid azide
• CAS NO: 119924-26-4
• Molecular Formula: C₇H₅N₃O₂
• Molecular Weight: 163.1335
• Mol File: 119924-26-4.mol

Chemical Properties

• Melting Point: 70-72 °C(Solv: ethyl ether (60-29-7); hexane (110-54-3))
• Appearance: /
• CAS DataBase Reference: furan-2-acrylic acid azide(CAS DataBase Reference)
• NIST Chemistry Reference: furan-2-acrylic acid azide(119924-26-4)
• EPA Substance Registry System: furan-2-acrylic acid azide(119924-26-4)

Safety Data

• Hazardous Substances Data: 119924-26-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Furan-2-acrylic acid azide is used as a reagent in organic synthesis for its ability to undergo various chemical reactions, enabling the preparation of diverse functionalized compounds.
Used in Chemical Research:
It is utilized in chemical research for its unique properties and reactivity, contributing to the development of new chemical methodologies and understanding of reaction mechanisms.
Used in Pharmaceutical Production:
Furan-2-acrylic acid azide is used as a building block in the production of pharmaceuticals, taking advantage of its reactivity and functional group to create novel drug molecules.
Used in Agricultural Chemicals:
It is employed in the development of agricultural chemicals, where its reactivity and functional group can be leveraged to create new compounds with desired properties for crop protection or enhancement.
Used in Materials Chemistry:
Furan-2-acrylic acid azide is used in materials chemistry for the synthesis of new materials with specific properties, such as improved mechanical strength, thermal stability, or other desirable characteristics.
Safety Note:
Due to the potential hazards and explosive nature of azides, furan-2-acrylic acid azide should be handled with extreme caution to ensure safety in research and industrial applications.

Upstream product

• 539-47-9 3-(2-furyl)acrylic acid 
• 98-01-1 furfural 
• 541-41-3 chloroformic acid ethyl ester 
• 539-47-9 3-(fur-2-yl)crotonic acid 
• 519054-08-1 (E)-1-(1H-1,2,3-benzotriazol-1-yl)-3-(2-furyl)-2-propen-1-one 
• 20689-54-7 (E)-3-(2-furyl)acryloyl chloride 

Downstream Products

• 603301-02-6 7-bromofuro[3,2-c]pyridine-4(5H)-one 
• 26956-43-4 furo[3,2-c]pyridine-4-ol 
• 31270-80-1 4-chlorofuro[3,2-c]pyridine 
• 76311-99-4 4-phenylfuro<3,2-c>pyridine 
• 271-92-1 furo[3,2-c]pyridine 
• 86518-10-7 acetyl-2 chloro-4 furo<3,2-c>pyridine 
• 84400-99-7 7-Chlorofuro[2,3-c]pyridine 
• 26956-43-4 5H-furo[3,2-c]pyridin-4-one 

Relevant articles and documents

Preparation of polyfunctional acyl azides

(Chemical Equation Presented) A general synthesis of acyl azides from the corresponding N-acyl benzotriazoles is described. The procedure affords acyl azides in good yields and avoids the use of acid activators and NO+ equivalents typically emp

A novel furo[3,2-: C] pyridine-based iridium complex for high-performance organic light-emitting diodes with over 30% external quantum efficiency

A novel furo[3,2-c]pyridine based Ir complex, namely (pfupy)2Ir(acac), has been developed by replacing sulfur with oxygen in the C^N ligand. Compared with the thiophene-containing (pthpy)2Ir(acac), the LUMO level is elevated while the HOMO level remains almost unchanged for the resultant furan-containing (pfupy)2Ir(acac). As a consequence, the emissive maximum is blue-shifted from 556 nm of (pthpy)2Ir(acac) to 538 nm of (pfupy)2Ir(acac) together with an improved photoluminescence quantum yield of 0.80. The corresponding device based on (pfupy)2Ir(acac) realizes a record-high external quantum efficiency (EQE) of 30.5% (110.5 cd A-1) without any out-coupling technology. Even at a luminance of 1000 and 5000 cd m-2, the EQE still remains at 26.6% (96.4 cd A-1) and 25.6% (92.7 cd A-1), respectively, indicative of the gentle efficiency roll-off. The results clearly demonstrate the great potential of furan-based functional materials applied in OLEDs.

NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT

Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

TRICYCLIC COMPOUND AND MEDICAL USE THEREOF

The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s), R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or mercapto optionally having a substituent, Xa to Xe are each a carbon atom or a nitrogen atom, m is 0 to 2, and ring A to ring C are each a ring optionally having substituent(s), or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.

AZABENZOFURAN SUBSTITUTED THIOUREAS; INHIBITORS OF VIRAL REPLICATION

The present invention provides compounds of Formula: (1), wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W, X, and Y are defined herein. Certain compounds of Formula (1

NOVEL CHEMICAL COMPOUNDS

This invention relates to newly identified compounds for treating and preventing tumors ans cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.

Thieno and furopyridinium-substituted cephalosporins

Cephalosporin compounds substituted in the 7-position by a 2-(5- or 6-membered heterocyclic)-2-oximinoacetylamino group and in the 3-position with a thienopyridinium methyl group or a furopyridinium methyl group are broad spectrum antibiotics highly effective in combating bacterial infections of gram-negative and gram-positive microorganisms. The cephalosporins are best prepared by reacting a silylated 7-[2-(heterocyclic)-2-oximinoacetylamino-3-iodomethyl-3-cephem-4-carboxylic acid with the thienopyridine or the furopyridine. Pharmaceutical formulations comprising a compound of the invention and a method for treating bacterial infections comprising their use are also provided.

Oxazole and oxadiazole cephalosporins

Broad spectrum cephalosporin antibiotics represented by the betaine structure of the formula STR1 wherein R is a 5-membered amino-substituted heterocyclic containing oxygen and nitrogen; R' is e.g., hydrogen or C1 -C4 alkyl; and bicyclicpyridinium is a thienopyridinium or a furopyridinium group; are prepared by reacting a silylated 3-iodomethyl cephalosporin with a thienopyridine, e.g., thieno[2,3-b]pyridine or a furopyridine. The compounds are potent antibacterials against gram-positive and gram-negative organisms. Pharmaceutical compositions and a method for treating bacterial infections are also provided.